ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Keryx Biopharmaceuticals, Inc." (KERX) Report Updated: Aug 25, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Keryx Biopharmaceuticals, Inc." (KERX)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: ENTA, MDVN, RGEN, GILD

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Keryx Biopharmaceuticals, Inc."© quotemedia

Company Profile

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. The company’s products under development include KRX-0401 (perifosine), an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, as well as affects other pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Its KRX-0401 is in Phase III clinical development stage for the treatment of refractory advanced colorectal cancer and multiple myeloma, as well as in Phase I and Phase II clinical development stages for the treatment of other tumor types. The company is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that is in Phase III clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease on dialysis. Keryx Biopharmaceuticals, Inc. has commercial license agreements with Zentaris AG for the development of KRX-0401; Panion & BF Biotech, Inc. for the development and marketing of Zerenex; and Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. The company was founded in 1997 and is based in New York, New York.

Recent News: "Keryx Biopharmaceuticals, Inc."